SCHEMBL8188233

SCHEMBL8188233

CCOC(=O)c1nc2sc(Cc3ccccc3)cc2c(=O)[nH]1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.51
▸ KDM4E B2RXH2 3/20 0.51
▸ GAA P10253 3/20 0.51
▸ HPGD P15428 3/20 0.51
▸ CYP1A2 P05177 1/20 0.51
▸ POLB P06746 1/20 0.51
▸ CYP2C9 P11712 1/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.49
▸ PDE3B Q13370 1/20 0.46
▸ PDE3A Q14432 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ NPC1 O15118 1/20 0.44
▸ LMNA P02545 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ AGTR1 P30556 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ PDE5A O76074 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8198112 0.89 SMN1; SMN2 (0.47) ALDH1A1KDM4EGAAHPGDCYP1A2
SCHEMBL8190700 0.86 PDE5A (0.47) ALDH1A1SMN1; SMN2NPC1LMNAMAPT
SCHEMBL8200644 0.86 ALDH1A1 (0.57) ALDH1A1KDM4EGAAHPGDCYP1A2
SCHEMBL1967325 0.84 KDM4E (0.55) ALDH1A1KDM4EGAAHPGDCYP1A2
SCHEMBL11776313 0.83 ALDH1A1 (0.62) ALDH1A1KDM4EGAAHPGDCYP1A2
SCHEMBL11499215 0.82 ALDH1A1 (0.53) ALDH1A1KDM4EGAAHPGDCYP1A2
SCHEMBL11498504 0.81 ALDH1A1 (0.52) ALDH1A1KDM4EGAAHPGDCYP1A2
SCHEMBL166199 0.81 ALDH1A1 (0.60) ALDH1A1KDM4EGAAHPGDCYP1A2
SCHEMBL3491252 0.80 PDE5A (0.61) ALDH1A1KDM4ESMN1; SMN2PDE3BPDE3A
SCHEMBL11491036 0.80 ALDH1A1 (0.51) ALDH1A1KDM4EGAAHPGDCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7713966-B2 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2010-05-11 — — US disclosed
US-7713966-B2 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2010-05-11 — — US disclosed
US-20080261968-A1 Heterobicyclic metalloprotease inhibitors GEGE CHRISTIAN 2008-10-23 — — US disclosed
US-20080261968-A1 Heterobicyclic metalloprotease inhibitors GEGE CHRISTIAN 2008-10-23 — — US disclosed
WO-2008063668-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2008-05-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261968-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 ALDH1A1 1871/4885KDM4E 1572/4885GAA 328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback